熱門詞: 進口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進口電動高溫調(diào)節(jié)閥-德國進口電動高溫法蘭調(diào)節(jié)閥進口電動蒸汽調(diào)節(jié)閥-德國進口電動蒸汽調(diào)節(jié)閥
華海藥業(yè) Huahai Pharmaceuticals
浙江華海藥業(yè)股份有限公司創(chuàng)立于1989年,是一家集醫(yī)藥制劑和原料藥為一體的制藥企業(yè),2003年在上交所上市。目前,公司注冊資本5.4億元,總資產(chǎn)24.7億元,占地面積120多萬平方米,并在美國、上海、江蘇、杭州等地設有11家分(子)公司,共有員工3800多人。
公司是國家重點高新技術(shù)企業(yè),國家創(chuàng)新型企業(yè),浙江省醫(yī)藥工業(yè)十強企業(yè),中國民營500強企業(yè),“十一五”期間中國醫(yī)藥行業(yè)國際化先導企業(yè),設有“國家級企業(yè)技術(shù)中心”、“博士后科研工作站”,是中國首家榮獲“國家環(huán)境友好企業(yè)”稱號的醫(yī)藥企業(yè)。
華海藥業(yè)在國內(nèi)首家制劑通過美國FDA認證,并自主擁有ANDA制劑文號,是目前國內(nèi)通過美國FDA、歐洲COS、澳大利亞TGA等國際主流市場官方認證最多的制藥企業(yè)之一,在制劑出口以及國際化發(fā)展領域走在了國內(nèi)醫(yī)藥行業(yè)的前列,是目前中國唯一一家能夠進行大規(guī)模、商業(yè)化制劑生產(chǎn)及出口歐美市場的制藥企業(yè)。
公司是國內(nèi)特色原料藥行業(yè)的龍頭企業(yè),特別是心血管普利類、沙坦類藥物領域,公司擁有核心技術(shù),目前在國際上生產(chǎn)品種最多,技術(shù)水平領先,是全球最大的普利類和沙坦類藥物供應商。
2011年度,公司實現(xiàn)銷售收入約18.3億元,比去年同期增長78.7%,實現(xiàn)利稅約3.8億元,比去年同期增長70%。
Zhejiang Huahai Pharmaceuticals Co., Ltd.was initially founded in 1989, and the company's stock was successfully listed in Shanghai Stock Exchange in March, 2003.
Huahai Pharmaceuticals, a large scaled modern pharmaceutical group that integrates fomulations, APIs(Active Pharmaceutical Ingredients) and intermediates, is developing both domestic and international markets, and performing parallel development of science, industry and commerce. With a total asset of 1,900 million yuan, the company has 11branches (subsidiaries) in the United States, Shanghai, Hangzhou, and Linhai. It occupies an area of 800,000 square meters, and has a staff of 3400. The company is entitled as National Key Hi-tech Enterprise,National Pilot Enterprise of Innovation, and China's top 500 private enterprises, and possesses a "State Certified Enterprise Technology Center".
Huahai Pharmaceuticals is the largest supplier of pril products worldwide, with the annual production capacities of its dominating products "captopril" and "enalapril" both ranking first in the world. It is also the only manufacturer in the world that can realize commercial production of captopril, enalapril and lisinopril at the same time, enjoying the reputation of a "Pril Specialist". The pril drugs of the company boast absolute advantages in international markets in terms of production scale, product quality, technological skills and R&D.
The company's workshops of formulation are designed in strict compliance with the international cGMP standard, where the most advanced automatic pharmaceutical production equipment in the world was introduced. We are the first pharmaceutical company in China that has passed USA FDA approval.